PF-Atlas › Treatments › Aberrant Basaloid Cell Elimination

Aberrant Basaloid Cell Elimination

Target LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal source

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Mechanism class
Target LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal source
Timeline
2-4 years
Risk profile
Medium
Developer
Novel
Key researchers
Multiple

Overview

KRT17+/LAMB3+ basaloid cells drive fibrosis at active margins. Specific surface markers enable targeted elimination.

How Aberrant Basaloid Cell Elimination fits into IPF treatment

Aberrant Basaloid Cell Elimination is classified as Level 3 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:

Aberrant Basaloid Cell Elimination drug profileTarget LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal sourceClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Aberrant Basaloid Cell Elimination for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.